Patents Assigned to Keto Patent Group, Inc.
  • Patent number: 11173138
    Abstract: In various implementations, beta-hydroxybutyrate, related compounds, and/or one or more other compounds may be administered to an individual to cause weight loss, weight maintenance, elevate blood ketone levels, maintain blood ketone levels, reduce blood glucose levels, maintain blood glucose levels, improve energy, focus, mood, cognitive function, or aide with neurological or inflammatory disorders and/or combinations thereof. Other compounds may include short chain fatty acids, short chain triglycerides, medium chain fatty acids, medium chain triglycerides, long chain fatty acids, long chain triglycerides, berberine, metabolites of berberine (e.g., dihydroberberine), and/or combinations thereof.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: November 16, 2021
    Assignee: Keto Patent Group, Inc.
    Inventors: Ryan Lowery, Jacob Wilson
  • Patent number: 11026929
    Abstract: In various implementations, berberine metabolites, such as dihydroberberine and/or tetrahydroberberine, may be administered to manage blood glucose levels, increase ketone levels (e.g., blood concentration of ketones), and/or for therapeutic purposes in humans. The administration of a pharmaceutically effective amount of berberine metabolites, such as dihydroberberine, may reduce fasting blood glucose levels, improve glucose tolerance, and/or improve blood ketone response. In some implementations, berberine metabolites may be administered with one or more other compounds.
    Type: Grant
    Filed: May 6, 2019
    Date of Patent: June 8, 2021
    Assignee: Keto Patent Group, Inc.
    Inventors: Ryan Lowery, Jacob Wilson, Terry LaCore
  • Patent number: 10278961
    Abstract: In various implementations, berberine metabolites, such as dihydroberberine and/or tetrahydroberberine, may be administered to manage blood glucose levels, increase ketone levels (e.g., blood concentration of ketones), and/or for therapeutic purposes in humans. The administration of a pharmaceutically effective amount of berberine metabolites, such as dihydroberberine, may reduce fasting blood glucose levels, improve glucose tolerance, and/or improve blood ketone response. In some implementations, berberine metabolites may be administered with one or more other compounds.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: May 7, 2019
    Assignee: Keto Patent Group, Inc.
    Inventors: Ryan Lowery, Jacob Wilson, Shawn Wells, Terry LaCore